These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30971550)

  • 1. Distribution of common BCR-ABL fusion transcripts and their impact on treatment response in Imatinib treated CML patients: A study from India.
    Sazawal S; Chhikara S; Singh K; Chaubey R; Mahapatra M; Seth T; Saxena R
    Indian J Pathol Microbiol; 2019; 62(2):256-260. PubMed ID: 30971550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simple multiplex RT-PCR for identifying common fusion BCR-ABL transcript types and evaluation of molecular response of the a2b2 and a2b3 transcripts to Imatinib resistance in north Indian chronic myeloid leukemia patients.
    Mir R; Ahmad I; Javid J; Zuberi M; Yadav P; Shazia R; Masroor M; Guru S; Ray PC; Gupta N; Saxena A
    Indian J Cancer; 2015; 52(3):314-8. PubMed ID: 26905124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of BCR/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients.
    Khazaal MS; Hamdan FB; Al-Mayah QS
    Mol Genet Genomic Med; 2019 Aug; 7(8):e809. PubMed ID: 31206255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir.
    Azad NA; Shah ZA; Pandith AA; Khan MS; Rasool R; Rasool J; Aziz SA
    Asian Pac J Cancer Prev; 2018 Jun; 19(6):1479-1485. PubMed ID: 29936718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the Major BCR-ABL1 Transcript Type on Clinical and Biological Parameters and Molecular Response in Patients With Chronic Myeloid Leukemia.
    Nachi M; Kihel I; Entasoltane B; Brahimi M; Yafour N; Guella D; Abed A; Bekadja MA
    Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):58-62. PubMed ID: 32971032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.
    Haaß W; Kleiner H; Weiß C; Haferlach C; Schlegelberger B; Müller MC; Hehlmann R; Hofmann WK; Fabarius A; Seifarth W; ;
    PLoS One; 2015; 10(6):e0129648. PubMed ID: 26087013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts.
    Sharma P; Kumar L; Mohanty S; Kochupillai V
    Ann Hematol; 2010 Mar; 89(3):241-7. PubMed ID: 19714331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia.
    Lin HX; Sjaarda J; Dyck J; Stringer R; Hillis C; Harvey M; Carter R; Ainsworth P; Leber B; Pare G; Sadikovic B
    Eur J Haematol; 2016 Apr; 96(4):360-6. PubMed ID: 26059983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytogenetic & molecular analyses in adult chronic myelogenous leukaemia patients in north India.
    Anand MS; Varma N; Varma S; Rana KS; Malhotra P
    Indian J Med Res; 2012; 135(1):42-8. PubMed ID: 22382182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia.
    Bennour A; Ouahchi I; Achour B; Zaier M; Youssef YB; Khelif A; Saad A; Sennana H
    Med Oncol; 2013 Mar; 30(1):348. PubMed ID: 23269583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR-ABL Gene Transcript Types of Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia.
    Paramita DK; Hutajulu SH; Syifarahmah A; Sholika TA; Fatmawati S; Aning S; Sulistyawati D; Wahyuni S; Taroeno-Hariadi KW; Kurnianda J
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1545-1550. PubMed ID: 32592347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia.
    de Lemos JA; de Oliveira CM; Scerni AC; Bentes AQ; Beltrão AC; Bentes IR; Azevedo TC; Maradei-Pereira LM
    Genet Mol Res; 2005 Dec; 4(4):803-11. PubMed ID: 16475128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of BCR-ABL fusion transcripts in Sudanese patients with chronic myeloid leukemia using real-time reverse transcription-polymerase chain reaction.
    Muddathir AM; Kordofani AA; Fadl-Elmula IM
    Saudi Med J; 2013 Jan; 34(1):29-33. PubMed ID: 23299156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
    Gui X; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):210-4. PubMed ID: 24666486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia.
    Yaghmaie M; Ghaffari SH; Ghavamzadeh A; Alimoghaddam K; Jahani M; Mousavi SA; Irvani M; Bahar B; Bibordi I
    Arch Iran Med; 2008 May; 11(3):247-51. PubMed ID: 18426313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of Bcr-abl type transcript and its relationship with platelet count in Mexican patients with chronic myeloid leukemia].
    Rosas-Cabral A; Martínez-Mancilla M; Ayala-Sánchez M; Vela-Ojeda J; Bahena-Reséndiz P; Vadillo-Buenfil M; Aviña-Zubieta JA; Salazar-Exaire D; Miranda-Peralta E; Marroquín A; Longoria-Revilla E
    Gac Med Mex; 2003; 139(6):553-9. PubMed ID: 14723051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
    Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
    Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib.
    Popovici C; Cailleres S; David M; Lafage-Pochitaloff M; Sainty D; Mozziconacci MJ
    Leuk Lymphoma; 2005 Sep; 46(9):1375-7. PubMed ID: 16109618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of BCR::ABL1 Transcripts in the Different Clinical Phases of Chronic Myeloid Leukemia: Effect on Hematological Parameters and Patient Survival.
    Romero-Morelos P; González-Yebra AL; Herrerías-García A; Ruíz-Velázquez FA; Bueno-Rosario LJ; González-Yebra B
    Genes (Basel); 2024 Apr; 15(5):. PubMed ID: 38790196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11).
    Mundhada S; Luthra R; Cano P
    BMC Cancer; 2004 Jun; 4():25. PubMed ID: 15202948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.